Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, climbed after signing a collaboration agreement to develop a potential peptide vaccine against COVID-19
A collaboration agreement for a potential COVID-19 vaccine powered a Canadian biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, May 5, 2020 (as of 4 pm EST):
Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, jumped as much as 22% before ending up 4% at $0.14 on Tuesday after announcing that it has signed a collaboration agreement with The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center to advance Vaxil’s research program to develop a potential peptide vaccine against COVID-19.
As well, shares of MEG Energy Corp. (TSX:MEG) gained 16% to $3.38 as the in situ thermal oil producer said it generated first-quarter free cash flow of $24 million and added that it currently expects first half 2020 production to average approximately 76,000 bbls/d.
Eguana Technologies (TSXV:EGT), meanwhile, reported $2.4 million in new orders, predominantly for Hawaii and California, which are expected to ship over the next two to three months. Eguana Technologies stock moved up 17% to $0.07 following the announcement.
Finally, Gold X Mining Corp. (TSXV:GLDX) shares climbed 18% to $2.48 after the gold junior announced that it has begun permitting work on its Toroparu Project in Guyana and is fully funded to fast track a Feasibility Study in order to make a production decision.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, jumped as much as 22% before ending up 4% at $0.14 on Tuesday after announcing that it has signed a collaboration agreement with The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center to advance Vaxil’s research program to develop a potential peptide vaccine against COVID-19.
, on Tuesday.){kind=link}